09Sep 2023
Non-Impact of Secondary-Type Mutations on NPM1-Mutated AML Outcomes

Non-Impact of Secondary-Type Mutations on NPM1-Mutated AML Outcomes

In 2022, the European LeukemiaNet (ELN) unveiled its second update to the risk classification for Acute Myeloid Leukemia (AML), marking a significant milestone since its inception in 2010. ELN2022 designates "secondary-type" mutations (STMs) as adverse risk factors. This classification aligns with recent World Health Organization (WHO) and International Consensus Classification (ICC) updates. However, questions emerged about the interplay between STMs and favorable markers like NPM1 mutations. Research on a multicenter cohort of 936 NPM1-mutated AML patients revealed that STMs do not negate the favorable prognosis associated with NPM1 mutations. This study supports ELN's classification of NPM1-mutated patients as favorable, even in the presence of STMs.

  • #oncology

Like

Save

Share